STOCK TITAN

XENE (NASDAQ: XENE) insider sale notice shows 20,000 vested shares to sell

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

XENE filed a Form 144 to sell 20,000 common shares tied to a performance share unit award that vested on 03/09/2026.

The filing lists prior proposed or completed sales by Ian Mortimer of 40,000 shares on 01/02/2026 and 270,000 shares on 03/09/2026. The notice names Morgan Stanley Wealth Management Canada Inc. as the broker and shows the securities as Common Shares to be sold on NASDAQ.

Positive

  • None.

Negative

  • None.

Insights

Form 144 shows a proposed sale of 20,000 vested performance shares and recent large dispositions by the same individual.

The filing records a proposed sale of 20,000 common shares tied to a performance share unit vesting on 03/09/2026. It also lists prior transactions: 40,000 shares on 01/02/2026 and 270,000 shares on 03/09/2026.

Cash‑flow treatment and whether these are planned transactions under a trading plan are not stated in the excerpt; subsequent filings or trade reports would show execution details and net proceeds.

The notice reflects routine insider resale disclosure tied to vested compensation rather than a corporate action.

The 144 lists the securities as Common Shares and specifies the reason as "Performance share unit award vesting." That links the sale to compensation vesting rather than a company capital‑markets transaction.

Role of the broker is shown as Morgan Stanley Wealth Management Canada Inc.; any market impact depends on whether the shares are actually sold and on execution details not included here.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does XENE's Form 144 report?

It reports a proposed sale of 20,000 common shares tied to a performance share unit vesting on 03/09/2026. The filing names Morgan Stanley Wealth Management Canada Inc. as the broker and designates the shares for NASDAQ trading.

Who is listed as the selling party in the Form 144 for XENE?

The filing identifies transactions by Ian Mortimer, including prior sales of 40,000 shares on 01/02/2026 and 270,000 shares on 03/09/2026. The current notice covers 20,000 vested shares.

Are the 20,000 shares being sold from compensation or other sources?

They are tied to a performance share unit award vesting on 03/09/2026, indicating the shares originate from vested compensation. The filing text links the sale reason explicitly to that vesting event.

Does the Form 144 state who will receive the proceeds from the sale?

The excerpt does not state proceeds recipients. The filing lists the issuer and broker, but cash‑flow treatment is not specified in the provided content.

Which broker is named for the proposed sale in XENE's Form 144?

Morgan Stanley Wealth Management Canada Inc. is listed as the broker on the Form 144 for the proposed sale of the 20,000 common shares tied to the vesting.
Xenon Pharmaceut

NASDAQ:XENE

View XENE Stock Overview

XENE Rankings

XENE Latest News

XENE Latest SEC Filings

XENE Stock Data

5.04B
82.14M
Biotechnology
Pharmaceutical Preparations
Link
Canada
BURNABY